[{"Assets_0_Q2_USD":278958000.0,"CommonStockSharesOutstanding_0_Q2_shares":19054000.0,"EarningsPerShareBasic_1_Q2_USD":-0.28,"EarningsPerShareBasic_2_Q2_USD":-0.54,"EarningsPerShareDiluted_1_Q2_USD":-0.28,"EarningsPerShareDiluted_2_Q2_USD":-0.54,"NetIncomeLoss_1_Q2_USD":-5392000.0,"NetIncomeLoss_2_Q2_USD":-10372000.0,"StockholdersEquity_0_Q2_USD":266011000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":19047000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":19042000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":19047000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":19042000.0,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20170510"}]